Large Bitcoin traders on Hyperliquid have amassed over $892 million in short positions, nearly double their long bets, marking the strongest bearish stance since October 2025. This heavy shorting, clustered around the $83,000 price level, raises the risk of a short squeeze if Bitcoin's price rises, forcing shorts to buy back and potentially driving prices higher rapidly. Persistent negative funding rates indicate the bearish side is crowded and costly to hold, increasing pressure on shorts. Investors should watch funding rates, whale positioning, and price moves toward $83,000 for signs of a squeeze or shift in market sentiment.
Regarding the large leveraged Bitcoin shorts near $83K, here is Pluang's market snapshot as of Nov 10, 2026 19:44 WIB: Among 50 major cryptocurrencies priced on Pluang, 30 rose and 19 fell today. Notable movers include ENJ (Enjin Coin) at Rp419 with a 1-day change of -3.69% and 100% buy order activity, ATOM (Cosmos) at Rp25,108 with +3.57% change and 62% buy orders, and BCH (Bitcoin Cash) at Rp4,263,079 with -3.07% change and 90% buy orders.
project44 has partnered with Snowflake to enhance supply chain decision-making through Mo, an AI-powered supply chain analyst. Mo uses project44's extensive logistics data and Snowflake Cortex AI to provide accurate, consistent answers to complex sup...
H&R Block has launched the Emerald Advance Loan, a fixed-rate short-term loan up to $1,750 with a 35.90% APR, designed to help families cover year-end expenses without monthly payments. Borrowers repay the loan in full by March 31, 2027, with no impa...
Duke Robotics has entered a strategic collaboration with Greek security firm CRONOS to commercialize its Insulator Cleaning Drone (IC Drone) technology in Greece. This partnership leverages CRONOS's strong presence in Greece's critical infrastructure...
Alm. Brand A/S repurchased 1,369,397 shares between November 3 and 9, 2026, at an average price of DKK 17.46 per share. This is part of their announced buy-back program totaling up to DKK 593 million, aiming to reduce the number of outstanding shares...
Novartis has secured first place in the 2026 Access to Medicine Index, maintaining its lead since 2024 by excelling across all assessed technical areas, including governance, R&D, and product delivery. The company scored 3.86 out of 5 overall, with a...
